PROPOSED ADOPTION OF RESTRICTED SHARE UNIT INCENTIVE SCHEME

Boan Biotech Announces CDE Acceptance of Phase Ⅱ Clinical Trial Application for BA1106 in Combination with BA1104 for NSCLC

Yantai, April 4th, 2026 –- Boan Biotech announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted the application for a Phase ...

VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

(1) RESIGNATION OF EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEE

Boan Biotech Announces 2025 Financial Results

●Accelerated and upgraded innovation●Empowerment through partnerships●Two consecutive years of profitabilityYantai, China, March 30, 2026 — Boan Biotech (6955.HK) today announced its annual result...

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

NOTICE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026